Previous Article | Next Article ![]()
Journal of Clinical Microbiology, August 2001, p. 2891-2896, Vol. 39, No. 8
Department of Biomedical
Sciences,1 Department of Microbiological
and Gynecological Sciences,3 and
Microbiological Laboratory, Policlinico,4
University of Catania, Catania, Italy, and School of
Biosciences, Cardiff University, Cardiff, Wales, United
Kingdom2
Received 17 January 2001/Returned for modification 14 March
2001/Accepted 7 May 2001
The prevalence, epidemiology, and genomovar status of
Burkholderia cepacia complex strains recovered from
Italian cystic fibrosis (CF) patients were investigated using genetic
typing and species identification methods. Four CF treatment centers
were examined: two in Sicily, one in central Italy, and one in northern
Italy. B. cepacia complex bacteria were
isolated from 59 out of 683 CF patients attending these centers
(8.6%). For the two geographically related treatment centers in
Sicily, there was a high incidence of infection caused by a single
epidemic clone possessing the cblA gene and belonging to
B. cepacia genomovar III, recA group III-A, closely related to the major North America-United Kingdom clone,
ET12; instability of the cblA sequence was also
demonstrated for clonal isolates. In summary, of all the strains of
B. cepacia encountered in the Italian CF population, the
genomovar III, recA group III-A strains were the most
prevalent and transmissible. However, patient-to-patient spread was
also observed with several other genomovars, including strains of novel
taxonomic status within the B. cepacia complex. A
combination of genetic identification and molecular typing analysis is
recommended to fully define specific risks posed by the genomovar
status of strains within the B. cepacia complex.
Bacteria of the
Burkholderia cepacia complex have been increasingly isolated
as pathogens from cystic fibrosis (CF) patient populations due to their
capacity for spread between patients, and their potential role in
declining lung function with necrotizing pneumonia and frequently fatal
septicemia, the so-called B. cepacia syndrome, has also been
noted. Published reports indicate that different
Burkholderia strains, identified as B. cepacia by conventional laboratory procedures, may be associated
with a poor clinical prognosis for some individuals and/or with
enhanced person-to-person transmissibility (13).
Cross-infection between CF patients and epidemic outbreaks have been
documented both within and outside hospitals (8, 10).
Various markers have been associated with transmissible strains of
B. cepacia, such as extracellular appendages known as cable
pili (7, 20, 23) and a conserved 1.4-kb open reading frame
called esmR (B. cepacia epidemic strain marker [16]).
The taxonomic diversity and the peculiar genomic characteristics of
these organisms present diagnostic laboratories with many problems
(18, 28). The name "B. cepacia complex" was
proposed to comprise a cluster of five closely related species,
originally referred to as B. cepacia genomovars I through V
(6, 29). Recent research has also defined genomovar VI as
a new member of the B. cepacia complex which shares
considerable similarity with Burkholderia multivorans
(4), and the name Burkholderia ambifaria, for
bacteria belonging to genomovar VII (5), has been
proposed. Determination of the genomovar status of B. cepacia complex strains is based on a polyphasic
taxonomic approach encompassing traditional phenotypic and
genotypic tests (27, 28, 29). To simplify the
identification process, recent genetic procedures based on
nucleotide sequence polymorphisms of the 16S rRNA gene (1,
13, 14, 21) or the recA gene (18) have
been developed. Rapid and precise identification of bacteria is
essential to evaluate specific risks, in terms of clinical
prognosis and epidemicity, posed by each genomovar within the B. cepacia complex. Our study was performed in order to (i) evaluate
the prevalence of B. cepacia complex infection in CF
patients attending four Italian treatment centers over a period of 10 months, (ii) identify the genomovar status of each isolate, (iii) study
the epidemiological and genetic relatedness of Burkholderia
isolates, and (iv) evaluate the frequency of transmissibility markers
and their association with the epidemiological classification of the strains.
Bacterial strains and culture.
From September 1998 to July
1999, 683 patients were screened for B. cepacia complex
infection, by sputum cultures on oxidation-fermentation base polymyxin
B agar (Becton Dickinson). Strains were presumptively identified by the
API 20NE (Bio Merieux) system; positive cultures were then sent to our
reference laboratory for further characterization. A total of 92 B. cepacia isolates were obtained from the respiratory tract of patients attending the following CF centers: 28 were from 9 CF
patients from Catania, Sicily; 33 were from 33 CF patients hospitalized
in Palermo, Sicily; 1 isolate was from 1 CF patient in Gualdo Tadino,
central Italy; and 30 were from 22 CF patients in Milan, northern Italy.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.8.2891-2896.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Burkholderia cepacia Complex
Infection in Italian Patients with Cystic Fibrosis: Prevalence,
Epidemiology, and Genomovar Status
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Genomovar status identification based on the rRNA genes. Preliminary identification of genomovar status was performed on the basis of a previously published PCR-based procedure for the identification of sequence motifs within the 16S and 23S ribosomal DNAs (1). Three separate PCRs were run, including primers of different degrees of specificity, in order to achieve stepwise exclusion of single species: Ce-16-21028 excluded B. multivorans, Burkholderia vietnamiensis, and Burkholderia gladioli; Mu-Vi-16-21028 excluded B. cepacia; and Gl-16-2457 excluded B. cepacia, B. multivorans, and B. vietnamiensis.
Genomovar status identification based on the recA gene. A total of 53 strains, representative of the genetic diversity within the collection (determined by pulsed-field gel electrophoresis [PFGE]; see below), were examined (18). Briefly, identification of B. cepacia complex was carried out using PCR with primers which amplify the entire recA gene of bacteria within the B. cepacia complex. Genomovar status was then identified by RFLP of the amplified recA gene and confirmed using PCR primers specific for each genomovar. Strains that produced novel RFLP types and that tested negative with the genomovar-specific primers were subjected to nucleotide sequence analysis of the upstream region of the recA gene using PCR primers. Phylogenetic analysis of the resulting sequences was then used to place these strains within the complex. In addition, RFLP analysis of the 16S rRNA operon was performed on these strains to confirm their subclassification within genomovar I, III, or IV, B. multivorans, or B. vietnamiensis.
PFGE. DNA fingerprinting by PFGE was carried out by the method of Grothues et al. (9). In brief, isolates were grown overnight on nutrient agar and then suspended in 1 ml of SE buffer (75 mM NaCl, 25 mM EDTA, pH 7.5) and adjusted to 1010 CFU/ml. Cell suspensions were mixed with an equal volume of 1.6% low-melting-point agarose, molded into plugs at 4°C, and lysed at 56°C overnight; the DNA inserts were then digested with SpeI, according to the supplier's instructions (New England Biolabs). Macrorestriction fragments were separated using a Gene Navigator apparatus (Pharmacia Biotech) at 10°C for 19 h, with a start time of 5 s and an end-pulse time of 35 s, at a field strength of 6 V/cm. A concatemer ladder of lambda phage DNA was used as a size marker. Interpretation of genomic relatedness was performed using well-established criteria (22, 26).
PCR detection of cblA and esmR. Whole-cell DNA was amplified in a reaction mixture consisting of 200 µM deoxynucleoside triphosphates, 1 µM (each) primer, 1× PCR buffer (50 mM KCl, 10 mM Tris-HCl [pH 8.3], 1.5 mM MgCl2), 2.5 mM MgCl2, and 1 U of Taq DNA polymerase. Each mixture was overlaid with 50 µl of liquid paraffin and placed in a PT 100 thermal cycler. The primer sequences used to amplify the esmR gene were as previously described (16). DNA sequences were amplified as follows: 30 cycles of 1 min at 94°C, 1 min at 62°C, and 1 min at 72°C and a final extension step at 72°C for 5 min. For the amplification of the cblA gene, primers were as previously described (20). Amplification was done for 30 cycles, each consisting of 1 min at 94°C, 1 min at 58°C, and 1 min at 72°C.
| |
RESULTS |
|---|
|
|
|---|
Prevalence of B. cepacia complex bacteria. Our study involved 683 out of 2,717 patients (25%) included in the National Italian CF Register up to the end of 1995 (2, 25), under microbiological surveillance in CF treatment centers. From the initial biochemical screening performed in the four centers, the prevalence of B. cepacia infection was 9.5% overall (65 out of 683 patients): 30% (9 out of 30 patients) in Catania, 16.5% (33 out of 200 patients) in Palermo, 4% (1 out of 23 patients) in Gualdo Tadino, and 5% (22 out of 430 patients) in Milan. Further molecular characterization based on the 16S rRNA and recA gene (see below) indicated that isolates from six of these patients were not of the B. cepacia complex, providing a final prevalence of infection of 8.6% (59 out of 683 patients). Misidentification of B. cepacia complex was associated with all four CF treatment centers participating in this survey (Catania, Palermo, and Gualdo Tadino each contributing one misidentified strain and Milan contributing three non-B. cepacia complex bacteria).
Identification of Burkholderia spp. based on the 16S
rRNA gene.
A total of 92 isolates were identified as B. cepacia after routine biochemical tests. Preliminary molecular
identification based on the 16S rRNA gene was performed on all 92 CF
isolates. Briefly, 89 of these 92 isolates (97%) were found to belong
to B. cepacia genomovar I, III, or IV, these genomovars
not being discriminated. One strain (1%) was identified as
B. multivorans or B. vietnamiensis, and two (2%) were B. gladioli (Table 1).
|
Identification of B. cepacia complex genomovars
based on the recA gene.
Due to the inability of the
16S rRNA gene PCR to distinguish all the current genomovars, the
nucleotide sequence polymorphism in the recA gene was
analyzed to determine specific genomovar status (Table
2). Examination of the PCR-RFLP patterns
of the recA gene was performed first. Ten distinct
HaeIII-derived RFLP patterns were found among 53 isolates
that were representative of the genetic diversity of the B. cepacia complex strains present at the four CF centers (see PFGE
results below). Six of these RFLP patterns correlated with those
described previously, and their genomovar status was then confirmed
using the genomovar-specific primers and was as follows: RFLP type E,
genomovar I; RFLP type F, B. multivorans; RFLP type G,
genomovar III (recA group III-A); RFLP types H and I,
genomovar III (recA group III-B); and RFLP J,
Burkholderia stabilis. Four recA gene RFLP types
were not previously described and were designated RFLP types AZ, I3, S,
and U. Apart from amplification of the entire recA gene with
the B. cepacia complex-specific primers BCR1 and BCR2,
strains possessing these novel RFLP types failed to react with any of
the genomovar-specific recA PCR primers. To confirm the
status of these strains as members of the B. cepacia
complex, nucleotide sequence analysis of the 5' 527-bp region of the
recA gene was performed and phylogenetically analyzed. All
strains possessing novel recA RFLP types were members of the
B. cepacia complex based on recA
phylogenetic analysis. The resulting phylogenetic tree is shown in Fig.
1. However, using current methods these
strains have been found to have indeterminate genomovar status and may
be novel taxonomic groups within the B. cepacia
complex. To confirm this recA-based result, RFLP analysis of
the 16S rRNA gene was also performed. All strains of recA
RFLP types AZ, I3, S, and U possessed the 16S rRNA gene RFLP pattern 2 (data not shown). This 16S rRNA gene RFLP is shared by the control strains of genomovar I, genomovar III, B. ambifaria
(genomovar VII), and B. stabilis. However, none of
these novel strains possessed other phenotypic or genetic
characteristics associated with B. ambifaria or
B. stabilis; hence, they were identified as
B. cepacia complex genomovar I-III indeterminate status
(Fig. 1).
|
|
Final prevalence of each B. cepacia complex genomovar. Final genomovar status identification was attributed based on the recA polymorphism; the results, in comparison with the 16S rRNA gene analysis, are summarized in Table 2. B. cepacia genomovar III was the dominant species present among the Italian isolates examined (69.5%, 64 out of 92 isolates), and of these, the majority (80%, 51 out of 64 isolates) belonged to B. cepacia genomovar recA group III-A.
Genome macrorestriction analysis. On the basis of PFGE-based RFLP analysis, the epidemiology of B. cepacia strains was assessed. Serial isolates recovered from the same patients produced conserved macrorestriction patterns, demonstrating chronic persistence of individual strain types in 10 patients and recurrence of infection in 2 patients (data not shown).
Macrorestriction analysis enabled the identification of at least 27 different clones responsible for the spread of B. cepacia infection. Different epidemiological features, showing cross-transmission or sporadicity of infection, were present in each center (Table 3). A predominant clone was identified in the two Sicilian centers. This "Sicilian epidemic clone" (PFGE strain type A) chronically infected 26 of the 42 B. cepacia complex-positive patients (62%) attending the two treatment centers. This highly transmissible strain was not found outside Sicily. Its PFGE profile was closely related (similarity coefficient, 78%) to the C5424 reference strain, a member of the ET12 North America-United Kingdom transatlantic clone (Fig. 2A).
|
|
PCR detection of cblA and esmR. Within this study, the presence of published molecular markers of B. cepacia complex transmissibility was demonstrated for the first time within the Italian CF population (Table 1). Cable pilus-associated sequences were present in a total of 33 of the 92 isolates, all from the Sicilian centers, belonging to the B. cepacia genomovars III and I-III. Notably, the epidemic outbreak involving the two Sicilian centers was sustained by 26 different variants of the same genomovar III-A clone: 14 were cblA positive and esmR negative, 7 were cblA positive and esmR positive, 3 were cblA negative and esmR positive, and 2 were cblA negative and esmR negative (Fig. 2B). A total of 43 out of the 59 patients were colonized by B. cepacia complex strains as a result of epidemic spread or cross-transmission: for 23 of these patients, the strains involved were shown to bear the cblA gene, while the remaining 20 strains were cblA negative.
The presence of esmR sequences was shown for 40 of the 92 isolates examined, and all of these belonged to B. cepacia genomovar III: 22 of these esmR-positive strains were associated with epidemic spread, while the remaining 18 were not. Instability of both transmissibility markers within a single genomovar III-A clone was also observed (Fig. 2).Correlation between bacterial genomovar status and the epidemicity of infection. Using the genomovar status of each strain obtained by analysis of the recA gene, a correlation between the risk of patient-to-patient cross-infection and genomovar status was made. The highest correlation between cross-infection and genomovar was associated with strains of the B. cepacia complex genomovar III, recA group III-A. There were 43 patients sharing the same strain as a result of cross-infection: in 28 of these cases, the strain involved belonged to genomovar III, recA group III-A. A relative risk of cross-infection with genomovar III-A was calculated as 1.9 (28 cases associated with genomovar III-A compared to 15 cases associated with strains of the other genomovars). recA group III-A included epidemic CF strains from the cable pilus-encoding lineage (18, 20) and the Vancouver outbreaks (15, 17). Phylogenetic analysis of the recA gene sequence confirmed that the Catania cable pilus-carrying strain, responsible for the Sicilian epidemic, was within the same genetic cluster and closely related to these epidemic genomovar III-A strains (Fig. 1). A second genomovar III-A strain, of distinct PFGE type, was also responsible for cross-infection of two patients. Other instances of patients sharing the same strains were observed for B. cepacia of all the other genomovars except for B. multivorans (Table 3).
| |
DISCUSSION |
|---|
|
|
|---|
The worldwide increase of B. cepacia infection in CF patients suggests its epidemic spread, but the source and transmissibility of strains involved remain controversial. It has been suggested elsewhere that strains of the B. cepacia complex are not equally transmissible; rather, there exist highly transmissible lineages, presumably of a clonal nature, and heterogeneous lineages of negligible transmissibility (23). We investigated the hypothesis that transmissibility might be associated with a particular taxonomic group, genomovar or species, within the B. cepacia complex.
From our screening, the prevalence of infection of B. cepacia complex in CF patients in Italy was 8.6% overall, 18.3% in Sicily and 5% in Milan. The prevalence of B. cepacia infection, as reported in a survey published in 1997, was 3.8%, clearly underestimated, since at that time only a few laboratories used the selective culture media for isolation (24). A higher prevalence (20.5%) was reported from the Campania region, southern Italy, in 1999, when appropriate microbiological procedures were used, although identification was based on standard laboratory procedures (30).
Analysis of the recA gene of the B. cepacia complex is a more discriminatory molecular approach than the analysis of the 16S rRNA gene to identify isolates and evaluate the specific risk posed by infection with a given genomovar and the epidemic spread of infection. We evaluated this risk as being about twice that for infection sustained by microorganisms of genomovar III, recA group III-A, with respect to other strains of the complex. This group included the Sicilian epidemic clone, which was phylogenetically related to the ET12 North America-United Kingdom transatlantic clone.
Although infection of the majority of patients involved in the Sicilian outbreak was sustained by strains possessing the cblA gene, a genetic marker associated with transmissibility, 5 of the 26 patients involved were actually colonized with a cblA-negative variant of the same clone, suggesting that the region may be subject to some instability. The PFGE fingerprints of these cblA-negative variants of the type clone showed minor changes in their banding profile, which may be associated with genome rearrangement and loss of the cblA gene. Early studies of the B. cepacia genome showed pronounced genome plasticity due to its multiple replicon organization and large numbers of insertion sequences (12, 29). In light of the heavy use of genetic markers for the epidemiological management of B. cepacia complex infections in CF (3, 16, 20, 23), the stability of these markers must be better understood.
Our findings suggest that the esmR and the cblA sequences may be encoded on a chromosomal region which is unstable in some B. cepacia genomovar III epidemic strains. Genetic instability has been well documented for the esmR open reading frame (16, 18), while instability of the cblA gene had not been previously demonstrated.
In conclusion, we have demonstrated that genomovar III is the most prevalent genomovar of B. cepacia complex bacteria among a population of Italian CF patients as previously reported (28). We also observed CF infection and patient-to-patient spread of B. cepacia complex bacteria of novel taxonomic status. Genetic identification of bacteria recovered from clinical settings as well as from other sources is essential to further understanding of the transmissibility and pathogenic potential of different genomovars or species within the B. cepacia complex.
| |
ACKNOWLEDGMENTS |
|---|
This work was partially supported by a grant to A.A. and S.S. from the University of Catania (Progetti di Ricerca di Ateneo). E.M. is grateful to the UK Cystic Fibrosis Trust (project grant PJ472) for financial support.
We thank M. L. Garlaschi, Istituti Clinici di Perfezionamento, Milan; D. Natoli, A. Collura, and T. Pensabene, Ospedale G. Di Cristina, ARNAS, Palermo; C. Pasquarella, Dipartimento di Igiene di Perugia; and I. Collebrusco, Ospedale R. Calai, Gualdo Tadino, for sending strains included in the study. E.M. is grateful to Julie Fadden for her technical assistance. We are grateful to Antony Bridgewood for the critical English revision of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Section of Microbiology of the Department of Microbiological and Gynecological Sciences, University of Catania, Via Androne 81, 95124 Catania, Italy. Phone: 39 (095) 311352. Fax: 39 (095) 325032. E-mail: stefanis{at}mbox.unict.it.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bauernfeind, A.,
I. Schneider,
R. Jungwirth, and C. Roller.
1999.
Discrimination of Burkholderia multivorans and Burkholderia vietnamiensis from Burkholderia cepacia genomovars I, III, and V by PCR.
J. Clin. Microbiol.
37:1335-1339 |
| 2. | Bossi, A., R. Padoan, R. Gagliardini, A. Manca, M. Zanda, A. Miano, L. Marianelli, L. Romano, G. Magazzù, V. Raia, F. Pardo, G. Gazincich, D. Salvatore, S. Quattrucci, G. de Candusio, V. Lucidi, D. Faraguna, G. Mastella, and A. Giunta. 1995. The Italian cystic fibrosis patients registry, p. 39. In 20th European Cystic Fibrosis Conference, Brussels, Belgium, 18 to 21 June 1995. |
| 3. |
Clode, F. E.,
M. E. Kaufmann,
H. Malnick, and T. L. Pitt.
2000.
Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom.
J. Clin. Microbiol.
38:1763-1766 |
| 4. | Coenye, T., J. J. LiPuma, D. Henry, K. Vandemeulebroucke, M. Gillis, D. P. Speert, and P. Vandamme. 2001. Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int. J. Syst. Evol. Microbiol. 51(Part 2):271-279[Abstract]. |
| 5. | Coenye, T., E. Mahenthiralingam, D. Henry, J. J. LiPuma, S. Laevens, M. Gillis, D. P. Speert, and P. Vandamme. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex comprising biocontrol and cystic-fibrosis related isolates. Int. J. Syst. Evol. Microbiol., in press. |
| 6. |
Gillis, M.,
T. V. Van,
R. Bardin,
M. Goor,
P. Hebbar,
A. Willems,
P. Segers,
K. Kersters,
T. Heulin, and M. P. Fernandez.
1995.
Polyphasic taxonomy in the genus Burkholderia leading to an emended description of the genus and proposition of Burkholderia vietnamiensis sp. nov. for N2-fixing isolates from rice in Vietnam.
Int. J. Syst. Bacteriol.
45:274-289 |
| 7. |
Goldstein, R.,
L. Sun,
R. Jiang,
U. Sajjan,
J. Forstner, and C. Campanelli.
1995.
Structurally variant classes of pilus appendage fibers coexpressed from Burkholderia (Pseudomonas) cepacia.
J. Bacteriol.
177:1039-1052 |
| 8. | Govan, J. R. W., P. H. Brown, J. Maddison, C. J. Doherty, J. W. Nelson, M. Dodd, A. P. Greening, and A. K. Webb. 1993. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342:15-19[CrossRef][Medline]. |
| 9. | Grothues, D., U. Koopmann, H. Van der Hardt, and B. Tummler. 1988. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J. Clin. Microbiol. 26:115-123. |
| 10. | Holmes, A., R. Nolan, R. Taylor, R. Finley, M. Riley, R. Jiang, S. Steinbach, and R. Goldstein. 1999. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J. Infect. Dis. 179:1197-1205[CrossRef][Medline]. |
| 11. |
Johnson, W.,
S. Tyler, and K. Rozee.
1994.
Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping.
J. Clin. Microbiol.
32:924-930 |
| 12. | Lessie, T. G., W. Hendrickson, B. D. Manning, and R. Devereux. 1996. Genomic complexity and plasticity of Burkholderia cepacia. FEMS Microbiol. Lett. 144:117-128[CrossRef][Medline]. |
| 13. | LiPuma, J. J. 1998. Burkholderia cepacia. Management issues and new insights. Clin. Chest Med. 19:473-486[CrossRef][Medline]. |
| 14. |
LiPuma, J. J.,
B. J. Dulaney,
J. D. McMenamin,
P. W. Whitby,
T. L. Stull,
T. Coenye, and P. Vandamme.
2000.
Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients.
J. Clin. Microbiol.
37:3167-3170 |
| 15. | Mahenthiralingam, E., M. E. Campbell, D. A. Henry, and D. P. Speert. 1996. Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J. Clin. Microbiol. 34:2914-2920[Abstract]. |
| 16. | Mahenthiralingam, E., D. Simpson, and D. P. Speert. 1997. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J. Clin. Microbiol. 35:808-816[Abstract]. |
| 17. |
Mahenthiralingam, E.,
T. Coenye,
J. Chung,
D. P. Speert,
J. R. W. Govan,
P. Taylor, and P. Vandamme.
2000.
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex.
J. Clin. Microbiol.
38:910-913 |
| 18. |
Mahenthiralingam, E.,
J. Bischof,
S. K. Byrne,
C. Radomski,
J. E. Davies,
Y. Av-Gay, and P. Vandamme.
2000.
DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and II.
J. Clin. Microbiol.
38:3165-3173 |
| 19. |
Pitt, T. L.,
M. E. Kaufmann,
P. S. Patel,
L. C. A. Benge,
S. Gaskin, and D. M. Livermore.
1996.
Type characterization and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.
J. Med. Microbiol.
44:203-210 |
| 20. |
Sajjan, U.,
L. Sun,
R. Goldstein, and J. Forstner.
1995.
Cable (Cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers.
J. Bacteriol.
177:1030-1038 |
| 21. |
Segonds, C.,
T. Heulin,
N. Marty, and G. Chabanon.
1999.
Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of 16S rRNA gene and application to cystic fibrosis isolates.
J. Clin. Microbiol.
37:2201-2208 |
| 22. | Struelens, M. 1996. Consensus guidelines for appropriate use and evaluation of microbial epidemiologic typing systems. Clin. Microbiol. Infect. 2:2-11[Medline]. |
| 23. | Sun, L., R. Jiang, S. Steinbach, A. Holmes, C. Campanelli, J. Forstner, Y. Tan, M. Riley, and R. Goldstein. 1995. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat. Med. 1:661-666[CrossRef][Medline]. |
| 24. | Taccetti, G., and S. Campana. 1997. Microbiologic data of Italian cystic fibrosis patients. Eur. J. Epidemiol. 13:323-327[CrossRef][Medline]. |
| 25. | Taccetti, G., S. Campana, and L. Marianelli. 1999. Multiresistant non-fermentative Gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Eur. J. Epidemiol. 15:85-88[CrossRef][Medline]. |
| 26. | Tenover, F., R. Arbeit, R. Goering, P. Mickelsen, B. Murray, D. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239[Medline]. |
| 27. |
Vandamme, P.,
B. Pot,
M. Gillis,
P. de Vos,
K. Kersters, and J. Swings.
1996.
Polyphasic taxonomy, a consensus approach to bacterial systematics.
Microbiol. Rev.
60:407-438 |
| 28. |
Vandamme, P.,
B. Holmes,
M. Vancanneyet,
T. Coenye,
B. Hoste,
R. Coopman,
H. Revets,
S. Lauwers,
M. Gillis,
K. Kersters, and J. R. W. Govan.
1997.
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.
Int. J. Syst. Bacteriol.
47:1188-1200 |
| 29. |
Vandamme, P.,
E. Mahenthiralingam,
B. Holmes,
T. Coenye,
B. Hoste,
P. de Vos,
D. Henry, and D. P. Speert.
2000.
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV).
J. Clin. Microbiol.
38:1042-1047 |
| 30. | Villari, P., L. Iacuzio, E. A. Vozzella, V. Raia, and I. Torre. 1999. Epidemiologia di Burkholderia cepacia in pazienti con fibrosi cistica: primi risultati di uno studio comprendente la tipizzazione genotipica dei ceppi isolati. Ann. Ig. 11:501-506[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»